The Technical Analyst
Genocea Biosciences, Inc. [GNCA]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Genocea Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-85.71% $0.0001
/ 22 des 2022 @ 14:54
| RATING 2023-02-24 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0064 - 0.0076 ( +/- 1 166.67%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-02 | Duvall Diantha | Sell | 1 355 | Common Stock |
| 2022-06-02 | Flechtner Jessica Baker | Sell | 1 578 | Common Stock |
| 2022-06-02 | Clark William D | Sell | 4 023 | Common Stock |
| 2022-06-01 | Sumer Jacquelyn L | Sell | 2 500 | Common Stock |
| 2022-05-31 | Clark William D | Sell | 117 244 | Common Stock |
| INSIDER POWER |
|---|
| -100.00 |
| Last 92 transactions |
| Buy: 40 896 126 | Sell: 84 760 217 |
Forecast:
01:40 - $0.0040
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0001 (-85.71% ) |
| Volume | 0.0303 mill |
| Avg. Vol. | 0.0806 mill |
| % of Avg. Vol | 37.57 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GNCA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GNCA
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Latest Press Releases
2022-03-14 17:06:00 - Press Release
Genocea To Present At The 32nd Annual Oppenheimer Healthcare Conference
Cambridge, mass., march 14, 2022 (globe newswire) -- genocea biosciences, inc. (nasdaq: gnca), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that chip clark, president and chief executive officer, will present a corporate overview at the 32nd annual oppenheimer healthcare conference on thursday, march 17th at 8:40 a.m. et.
2022-03-08 17:39:00 - Press Release
Genocea To Present Clinical And Preclinical Data At Aacr Annual Meeting
Company to present late-breaking clinical trial update for titan trial of gen-011, genocea's neoantigen-targeted peripheral t cell therapy for solid tumors
2022-03-03 08:00:00 - Press Release
Genocea To Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast
Cambridge, mass., march 03, 2022 (globe newswire) -- genocea biosciences, inc. (nasdaq: gnca), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on thursday, march 10t h at 8:30 a.m. e.t.
2022-02-10 19:50:00 - Press Release
Genocea To Present At The 11th Annual Svb Leerink Global Healthcare Conference
Cambridge, mass., feb. 10, 2022 (globe newswire) -- genocea biosciences, inc. (nasdaq: gnca), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that chip clark, president and chief executive officer, will present a corporate overview at the virtual 11th annual svb leerink global healthcare conference on thursday, february 17th at 10:40 a.m. et.
2022-01-05 17:46:00 - Press Release
Genocea To Present At Upcoming Investor Conferences
Cambridge, mass., jan. 05, 2022 (globe newswire) -- genocea biosciences, inc. (nasdaq: gnca), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in january.
Latest News
2022-05-25 10:38:35 - InvestorPlace
Genocea Biosciences Is Shutting Down. What GNCA Stock Investors Should Know.
Genocea Biosciences (GNCA) stock is on the move Wednesday after the bioscience company revealed its shutting down and delisting shares. The post Genocea Biosciences Is Shutting Down.
2022-04-11 09:36:14 - PennyStocks
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-08 14:35:03 - Benzinga
Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients
Genocea Biosciences Inc (NASDAQ: GNCA) has shared initial data from Phase 1/2a TiTAN trial OF GEN-011 in patients with refractory solid tumors. The company says that the early results presented at American Association for Cancer Research (AACR) show anti-tumor activity despite the.
2022-03-14 17:06:00 - GlobeNewsWire
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference
CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17th at 8:40 A.M. ET.
2022-03-10 10:25:27 - Seeking Alpha
Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript
Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript
2022-03-08 17:39:00 - GlobeNewsWire
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea's neoantigen-targeted peripheral T cell therapy for solid tumors
2022-03-03 08:00:00 - GlobeNewsWire
Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10t h at 8:30 a.m. E.T.
2022-02-10 19:50:00 - GlobeNewsWire
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17th at 10:40 A.M. ET.
2022-01-05 17:46:00 - GlobeNewsWire
Genocea to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.
2021-11-10 19:26:00 - GlobeNewsWire
Genocea to Present at the Stifel 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17th at 1:20 PM ET.